about
Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.Antiatherogenic properties of metformin: the experimental evidence.Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers.Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants.Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety eEffect of substituting sesame meal for soybean meal on layer and broiler performanceProliferative effect of lipoprotein lipase on human vascular smooth muscle cellsLipoprotein lipase enhances human monocyte adhesion to aortic endothelial cellsDifferentiation of human monocytes to monocyte-derived macrophages is associated with increased lipoprotein lipase-induced tumor necrosis factor-alpha expression and production: a process involving cell surface proteoglycans and protein kinase CBeneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetesThe influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapyGliclazide inhibits differentiation-associated biologic events in human monocyte-derived macrophages
P50
Q33803331-AC996953-6C63-4187-8290-22124471CCE5Q34637395-554B3ADF-BFED-452F-8BCB-467D508B4430Q35539959-5C7C4DF6-757F-4AB7-8D48-4DF11B4F5EE4Q39816209-4EA13167-1525-4EEE-A8DF-B726A54676F0Q41683105-FD7054FB-089E-42BA-8F51-393C7AFFBC0EQ43184310-5D7FAC8E-9FE8-4E56-BC8B-FE91A405F00BQ43634154-50D94D16-F8F3-44D4-8663-78CFD9961CCBQ44799753-5B6D538A-182D-4B4B-9779-C9207FEB53F3Q46570591-FC0581CA-CD34-4C36-82D7-90FE946F3765Q56896227-DD6D56D6-69CA-4DC0-92F3-AD89F97B30B4Q72337840-C6640AF8-F22B-4358-8B87-CE44976B00EEQ73076597-0B968659-08E8-45E4-92BB-C2389CFBF96CQ73764698-08A0DE7D-CC78-4B92-BE50-BA02BE06F86BQ77862135-E522C204-E6AD-43ED-BAC5-5358ABE40EA7Q79474091-C8DF1774-1EDE-4165-ADDA-B62F81A00122Q83054376-496FC593-E366-4391-AECA-FAC0D91410B6Q83816275-2E2615A6-A1F6-4682-A579-3F9B5E6FFCEE
P50
description
researcher ORCID ID = 0000-0001-8493-959X
@en
wetenschapper
@nl
name
Jean-Claude Mamputu
@ast
Jean-Claude Mamputu
@en
Jean-Claude Mamputu
@es
Jean-Claude Mamputu
@nl
type
label
Jean-Claude Mamputu
@ast
Jean-Claude Mamputu
@en
Jean-Claude Mamputu
@es
Jean-Claude Mamputu
@nl
prefLabel
Jean-Claude Mamputu
@ast
Jean-Claude Mamputu
@en
Jean-Claude Mamputu
@es
Jean-Claude Mamputu
@nl
P106
P31
P496
0000-0001-8493-959X